T1	Participants 102 133	familial adenomatous polyposis.
T2	Participants 237 288	patients with familial adenomatous polyposis (FAP).
T3	Participants 752 765	FAP patients.
T4	Participants 887 1023	relevance-M66I, P153L, E158K, V257M, E305X, E308G, and R492W-in 21 and 20 FAP patients, who received sulindac and placebo, respectively.
T5	Participants 1044 1055	41 patients
T6	Participants 1186 1211	sulindac-treated patients
T7	Participants 1371 1391	patients on sulindac
